Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987
The HER-2/neu oncogene is a member of the erbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer.
Cited by 11,749 works. doi:10.1126/science.3798106
Authors
References
- Nonparametric Estimation from Incomplete Observations
- Nonparametric Estimation from Incomplete Observations
- Regression Models and Life-Tables
- Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
- Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene
- Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
- Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus
- Analysis of Survival Data under the Proportional Hazards Model
- Simian Sarcoma Virus onc Gene, v- sis , Is Derived from the Gene (or Genes) Encoding a Platelet-Derived Growth Factor
- Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes